Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052
In the period from April 5, 2021 up to and including April 9, 2021, a total of 1.200 shares of AlzChem Group AG were acquired as part of the share buyback program announced on February 2, 2021. The total number of shares acquired to date as part of this buyback amounts to 13.133. The acquisition was carried out by ODDO BHF Aktiengesellschaft, Frankfurt am Main/Germany via the stock exchange (XETRA) on behalf of AlzChem Group AG.
The total number of repurchased shares, the weighted average price and the aggregated volume per day were as follows:
|Buyback date||Total number of shares||Weighted average price (EUR)||Aggregated volume (EUR)|
This information as well as the detailed information on the individual daily transactions related to the buy-back program are also published on the Company's website at https://www.alzchem.com/en/investor-relations/stock/share-buy-back in accordance with Art. 2 par. 3 sentence 2 of Delegated Regulation (EU) 2016/1052.
Trostberg, April 12, 2021
AlzChem Group AG
AlzChem is a globally active specialty chemicals company that is predominantly among the market leaders in its fields of activity. AlzChem benefits in particular from the three very different global megatrends of sustainability, population growth and healthy aging. AlzChem products offer attractive solutions in a wide range of applications.
The company sees interesting growth prospects for itself above all in the fields of human and animal nutrition, pharmaceuticals, agriculture, fine chemicals, metallurgy and renewable energies. The broad product range includes, for example, dietary supplements, plant growth regulators and precursors for corona tests.
The company employs around 1,630 people at four production sites in Germany and Sweden, and at two sales companies in the USA and China. In 2020, AlzChem generated consolidated sales of around EUR 379 million and EBITDA of around EUR 53.8 million.
Further information about Investor Relations